Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

Anaptys Named a BioSpace 2024 Best Places to Work Winner

Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update

Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors